Congratulations to Dr. Jinglin Fu—awarded an NIH grant to develop nucleic-acid nanoparticles that deliver CRISPR/Cas9 to blood stem cells!
Backed by nearly $500,000 in NIH funding, Dr. Fu’s team is designing nucleic-acid nanoparticles to ferry genome-editing tools into hematopoietic (blood) stem cells. If successful, the approach could accelerate next-generation therapies for inherited disorders such as sickle-cell disease.
The work takes place in Fu’s Bio-Mimetic Design and Nanoscience Lab at the Joint Health Sciences Center, where chemistry, computation, and biology intersect daily. Students in the Chemistry and Molecular Technology M.S. and the Computational and Integrative Biology (CCIB) M.S. and Ph.D. programs will contribute directly—building complex macromolecular systems, testing targeted delivery, and modeling biochemical networks.
It’s a hallmark CCIB story: an interdisciplinary team, new tools for precision medicine, and meaningful opportunities for graduate researchers.